Literature DB >> 8392307

Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin.

H Tomioka1, H Saito, K Sato.   

Abstract

AM-1155 is a newly synthesized 6-fluoro-8-methoxy quinolone. We assessed its in vitro antimycobacterial activity using sparfloxacin (SPFX) and ofloxacin (OFLX) as comparison drugs. The MICs of these agents for various mycobacterial strains were determined by the agar dilution method with 7H11 medium. AM-1155 had lower MICs for 50 and 90% of tested strains of Mycobacterium kansasii, M. marinum, and M. fortuitum-M. chelonae complex than SPFX and OFLX, and the values for M. tuberculosis, M. scrofulaceum, and the M. avium-M. intracellulare complex were similar to those of SPFX and considerably lower than those of OFLX. In addition, the antimicrobial activity of AM-1155 against M. tuberculosis and M. intracellulare phagocytosed into murine peritoneal macrophages was compared with that of OFLX. AM-1155 (1 microgram/ml) inhibited the intracellular growth of both M. tuberculosis and M. intracellulare, whereas OFLX at the same concentration failed to show any such effect. Moreover, AM-1155 (10 micrograms/ml) exhibited a steady bactericidal action against M. tuberculosis, whereas OFLX at the same concentration had only a weak effect. AM-1155 (10 micrograms/ml) also inhibited the growth of M. intracellulare more effectively than OFLX.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8392307      PMCID: PMC187950          DOI: 10.1128/AAC.37.6.1259

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  Mycobacteria and the new quinolones.

Authors:  D C Leysen; A Haemers; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

2.  [In vitro and in vivo activities of norfloxacin, ofloxacin and ciprofloxacin against various mycobacteria].

Authors:  H Saito; K Sato; H Tomioka; T Watanabe
Journal:  Kekkaku       Date:  1987-05

Review 3.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

4.  In vitro activity of ciprofloxacin and ofloxacin against the Mycobacterium avium-intracellulare complex.

Authors:  S M Johnson; G D Roberts
Journal:  Diagn Microbiol Infect Dis       Date:  1987-05       Impact factor: 2.803

5.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

6.  Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis.

Authors:  M J Smith; L O White; H Bowyer; J Willis; M E Hodson; J C Batten
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

7.  In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.

Authors:  M Hosaka; T Yasue; H Fukuda; H Tomizawa; H Aoyama; K Hirai
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

8.  Ofloxacin and the treatment of pulmonary disease due to Mycobacterium fortuitum.

Authors:  S Ichiyama; M Tsukamura
Journal:  Chest       Date:  1987-12       Impact factor: 9.410

9.  Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.

Authors:  L B Heifets; P J Lindholm-Levy
Journal:  Tubercle       Date:  1987-12

10.  Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin.

Authors:  E A Gorzynski; S I Gutman; W Allen
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

View more
  13 in total

1.  In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria.

Authors:  R Schaumann; G Ackermann; B Pless; M C Claros; A C Rodloff
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

Review 2.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

3.  In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.

Authors:  N Miyashita; Y Niki; T Kishimoto; M Nakajima; T Matsushima
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

4.  Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.

Authors:  H Tomioka; K Sato; T Akaki; H Kajitani; S Kawahara; M Sakatani
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

5.  Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position.

Authors:  T E Renau; J W Gage; J A Dever; G E Roland; E T Joannides; M A Shapiro; J P Sanchez; S J Gracheck; J M Domagala; M R Jacobs; R C Reynolds
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

6.  Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans.

Authors:  M Nakashima; T Uematsu; K Kosuge; H Kusajima; T Ooie; Y Masuda; R Ishida; H Uchida
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

Review 7.  Pharmacokinetic factors in the modern drug treatment of tuberculosis.

Authors:  J G Douglas; M J McLeod
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

Review 8.  Gatifloxacin.

Authors:  C M Perry; J A Barman Balfour; H M Lamb
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

9.  In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a.

Authors:  H Saito; H Tomioka; K Sato; S Dekio
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

Review 10.  Activity of quinolones against mycobacteria.

Authors:  M R Jacobs
Journal:  Drugs       Date:  1995       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.